Video

Differences Between Motivational Interviewing and Traditional Patient Counseling Techniques

Bruce Berger, PhD, president of Berger Consulting LLC, discusses the major differences between motivational interviewing and traditional patient counseling techniques with respect to medication adherence.

Bruce Berger, PhD, president of Berger Consulting LLC, discusses the major differences between motivational interviewing and traditional patient counseling techniques with respect to medication adherence.

This video was recorded at the 2015 NACDS Total Store Expo.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
American Captial Building.
Related Content
FDA waives clinical efficacy studies for certain biosimilars -- Image credit: Kamitana | stock.adobe.com
September 2nd 2025

FDA to Waive Clinical Efficacy Studies for Monoclonal Antibody Biosimilars

Gillian McGovern, Associate Editor
Pharmacy Focus Oncology Edition Podcast
September 2nd 2025

Protecting Community Oncology Practices in the Wake of the IRA

Alexandra Gerlach, Associate Editor
FDA approves 2 denosumab biosimilars, Bildyos and Bilprevda -- Image credit: gguy | stock.adobe.com
September 2nd 2025

FDA Approves Bildyos and Bilprevda, Biosimilars of Reference Denosumab

Gillian McGovern, Associate Editor
From Guidelines to Action: Pharmacy’s Role in Hypertension Management
September 2nd 2025

From Guidelines to Action: Pharmacy’s Role in Hypertension Management

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP Aislinn Antrim, Managing Editor
Streptococcus pneumoniae, or pneumococcus, is a gram-positive bacteria responsible for many types of pneumococcal infections
September 2nd 2025

A Single Dose of Pneumococcal Conjugate Vaccine Is Effective Against IPD in Children

Luke Halpern, Assistant Editor
Alzheimer disease and lecanemab -- Image credit: HalynaRom | stock.adobe.com
September 2nd 2025

FDA Approves Subcutaneous Lecanemab Injection for Maintenance Dosing in Early Alzheimer Disease

Gillian McGovern, Associate Editor